Quetiapine modulates conditioned anxiety and alternation behavior in Alzheimer's transgenic mice

Current Alzheimer Research

Volumn 10, Issue 2, 2013, Pages 199-206

  Tempier, Adrien ^a,b   He, Jue ^a   Zhu, Shenghua ^a   Zhang, Ruiguo ^a,c   Kong, Lynda ^a   Tan, Qingrong ^c   Luo, Huanmin ^d   Kong, Jiming ^a   Li, Xin Min ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^d MEDICAL COLLEGE OF JINAN UNIVERSITY   (China)

Author keywords

Alzheimer's disease; APP PS1 double transgenic mice; Brain derived neurotrophic factor; Conditioned anxiety; Memory; Quetiapine

Indexed keywords

AMYLOID PRECURSOR PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; PRESENILIN 1; QUETIAPINE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASOLATERAL AMYGDALA; CONDITIONING; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; EXPERIENTIAL LEARNING; FEMALE; GENERALIZED ANXIETY DISORDER; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; MAZE TEST; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT TERM MEMORY;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANALYSIS OF VARIANCE; ANIMALS; ANTIPSYCHOTIC AGENTS; ANXIETY; AVOIDANCE LEARNING; BEHAVIOR, ANIMAL; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; DIBENZOTHIAZEPINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRINKING; DRUG ADMINISTRATION SCHEDULE; HUMANS; LEARNING DISORDERS; MAZE LEARNING; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; MUTATION; PRESENILIN-1; REACTION TIME; TIME FACTORS;

EID: 84874954551     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205011310020010     Document Type: Article

References (42)

1. Cantillon M, De La Puente AM, Palmer BW. Psychosis in Alzheimer's Disease. Semin Clin Neuropsychiatry 3: 34-40 (1998).
2. Scharre DW, Chang SI. Cognitive and behavioral effects of quetiapine in Alzheimer disease patients. Alzheimer Dis Assoc Disord 16: 128-130 (2002).
3. Wragg RE, Jeste DV. Overview of depression and psychosis in Alzheimer's disease. Am J Psychiatry 146: 577-587 (1989).
4. Storey E, Cappai R. The amyloid precursor protein of Alzheimer's disease and the Abeta peptide. Neuropathol Appl Neurobiol 25: 81-97 (1999).
5. Suh YH, Checler F. Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease. Pharmacol Rev 54: 469-525 (2002).
6. Van Gassen G, Annaert W. Amyloid, presenilins, and Alzheimer's disease. Neuroscientist 9: 117-126 (2003).
7. Fukumoto H, Rosene DL, Moss MB, Raju S, Hyman BT, Irizarry MC. Beta-secretase activity increases with aging in human, monkey, and mouse brain. Am J Pathol 164: 719-725 (2004).
8. Lazarov O, Robinson J, Tang YP, Hairston IS, Korade-Mirnics Z, Lee VM, et al. Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell 120: 701-713 (2005).
9. Wilquet V, De Strooper B. Amyloid-beta precursor protein processing in neurodegeneration. Curr Opin Neurobiol 14: 582-588 (2004).
10. Asai M, Hattori C, Iwata N, Saido TC, Sasagawa N, Szabó B, et al. The novel beta-secretase inhibitor KMI-429 reduces amyloid beta peptide production in amyloid precursor protein transgenic and wild-type mice. J Neurochem 96: 533-540 (2006).
11. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356 (2002).
12. Chapman PF, White GL, Jones MW, Cooper-Blacketer D, Marshall VJ, Irizarry M, et al. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat Neurosci 2: 271-276 (1999).
13. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274: 99-102 (1996).
14. Duff K, Eckman C, Zehr C, Yu X, Prada CM, Perez-tur J, et al. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature 383:710-713 (1996).
15. He J, Luo H, Yan B, Yu Y, Wang H, Wei Z, et al. Beneficial effects of quetiapine in a transgenic mouse model of Alzheimer's disease. Neurobiol Aging 30: 1205-1216 (2009).
16. Velligan DI, Newcomer J, Pultz J, Csernansky J, Hoff AL, Mahurin R, et al. Does cognitive function improve with quetiapine in comparison to haloperidol? Schizophr Res 53: 239-248 (2002).
17. Velligan DI, Prihoda TJ, Sui D, Ritch JL, Maples N, Miller AL. The effectiveness of quetiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard treatment settings. J Clin Psychiatry 64: 524-531 (2003).
18. Purdon SE, Malla A, Labelle A, Lit W. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neurosci 26: 137-149 (2001).
19. Rainer M, Haushofer M, Pfolz H, Struhal C, Wick W. Quetiapine versus risperidone in elderly patients with behavioural and psychological symptoms of dementia: efficacy, safety and cognitive function. Eur Psychiatry 22: 395-403 (2007).
20. Fujikawa T, Takahashi T, Kinoshita A, Kajiyama H, Kurata A, Yamashita H, et al. Quetiapine treatment for behavioral and psychological symptoms in patients with senile dementia of Alzheimer type. Neuropsychobiology 49: 201-204 (2004).
21. Garcia-Alberca JM, Pablo Lara J, Gonzalez-Baron S, Barbancho MA, Porta D, Berthier M. Prevalence and comorbidity of neuropsychiatric symptoms in Alzheimer's disease. Actas Esp Psiquiatr 36: 265-270 (2008).
22. Caballero J, Hitchcock M, Scharre D, Beversdorf D, Nahata MC. Cognitive effects of atypical antipsychotics in patients with Alzheimer's disease and comorbid psychiatric or behavioral problems: a retrospective study. Clin Ther 28: 1695-1700 (2006).
23. Katzman MA, Vermani M, Jacobs L, Marcus M, Kong B, Lessard S, et al. Quetiapine as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder: a flexibledose, open-label pilot trial. J Anxiety Disord 22: 1480-1486 (2008).
24. He J, Yang Y, Yu Y, Li X, Li XM. The effects of chronic administration of quetiapine on the methamphetamine-induced recognition memory impairment and dopaminergic terminal deficit in rats. Behav Brain Res 172: 39-45 (2006).
25. He J, Xu H, Yang Y, Zhang X, Li XM. Chronic administration of quetiapine alleviates the anxiety-like behavioural changes induced by a neurotoxic regimen of dl-amphetamine in rats. Behav Brain Res 160: 178-187 (2005).
26. He J, Xu H, Yang Y, Rajakumar D, Li X, Li XM. The effects of chronic administration of quetiapine on the phencyclidine-induced reference memory impairment and decrease of Bcl-XL/Bax ratio in the posterior cingulate cortex in rats. Behav Brain Res 168: 236-242 (2006).
27. Poltronieri SC, Zangrossi H, Jr., de Barros Viana M. Antipanic-like effect of serotonin reuptake inhibitors in the elevated T-maze. Behav Brain Res 147: 185-192 (2003).
28. Viana MB, Tomaz C, Graeff FG. The elevated T-maze: a new animal model of anxiety and memory. Pharmacol Biochem Behav 49: 549-554 (1994).
29. Yamada K, Noda Y, Hasegawa T, Komori Y, Nikai T, Sugihara H, et al. The role of nitric oxide in dizocilpine-induced impairment of spontaneous alternation behavior in mice. J Pharmacol ExpTher 276: 460-466 (1996).
30. Pugh PL, Richardson JC, Bate ST, Upton N, Sunter D. Noncognitive behaviours in an APP/PS1 transgenic model of Alzheimer's disease. Behav Brain Res 178: 18-28 (2007).
31. Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 4: 97-100 (1998).
32. Arendash GW, King DL, Gordon MN, Morgan D, Hatcher JM, Hope CE, et al. Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Brain Res 891: 42-53 (2001).
33. Gordon MN, King DL, Diamond DM, Jantzen PT, Boyett KV, Hope CE, et al. Correlation between cognitive deficits and Abeta deposits in transgenic APP+PS1 mice. Neurobiol Aging 22: 377-385 (2001).
34. Wang H, Xu H, Dyck LE, Li XM. Olanzapine and quetiapine protect PC12 cells from beta-amyloid peptide(25-35)-induced oxidative stress and the ensuing apoptosis. J Neurosci Res 81: 572-580 (2005).
35. Tong Y, Zhou W, Fung V, Christensen MA, Qing H, Sun X, et al. Oxidative stress potentiates BACE1 gene expression and A(beta) generation. J Neural Transm 112: 455-469 (2005).
36. Connor B, Young D, Yan Q, Faull RL, Synek B, Dragunow M. Brain-derived neurotrophic factor is reduced in Alzheimer's disease. Brain Res Mol Brain Res 49: 71-81 (1997).
37. Mattson MP. Pathways towards and away from Alzheimer's disease. Nature 430: 631-639 (2004).
38. Ou LC, Gean PW. Transcriptional regulation of brain-derived neurotrophic factor in the amygdala during consolidation of fear memory. Mol Pharmacol 72: 350-358 (2007).
39. Broad KD, Mimmack ML, Keverne EB, Kendrick KM. Increased BDNF and trk-B mRNA expression in cortical and limbic regions following formation of a social recognition memory. Eur J Neurosci 16: 2166-2174 (2002).
40. Mizuno M, Yamada K, He J, Nakajima A, Nabeshima T. Involvement of BDNF receptor TrkB in spatial memory formation. Learn Mem 10: 108-115 (2003).
41. Xu H, Qing H, Lu W, Keegan D, Richardson JS, Chlan-Fourney J, et al. Quetiapine attenuates the immobilization stress-induced decrease of brain-derived neurotrophic factor expression in rat hippocampus. Neurosci Lett 321: 65-68 (2002).
42. Fumagalli F, Molteni R, Bedogni F, Gennarelli M, Perez J, Racagni G, et al. Quetiapine regulates FGF-2 and BDNF expression in the hippocampus of animals treated with MK-801. Neuroreport 15: 2109-2112 (2004).